🇪🇸 ES🇬🇧 EN
Teva Pharmaceuticals

Automation of Medical Materials and Regulatory Compliance: Dynamic URL and CloudPages System in Salesforce Marketing Cloud

Product Lead

3 months Salesforce Marketing Cloud, CloudPages, AMPscript, Compliance Automation, Regulatory Affairs, Medical Content Management, Dynamic URLs, Digital Asset Optimization, Marketing Operations, Data Governance, Omnichannel Content

The Challenge

In the pharmaceutical sector, regulatory compliance is critical. The medical and marketing teams faced a recurring problem: managing physical and digital materials that included references to summaries of product characteristics (SmPCs) or regulated medical documents.

By regulation, these materials had to contain up-to-date links to the most recent version of the technical data sheets. However, these could change several times a year, resulting in:

  • Obsolete URLs and out-of-date materials distributed in the market.
  • Risk of non-compliance by failing to reflect the latest information.
  • High operational and environmental costs from collecting, destroying and printing new materials.
  • Strain on sales teams forced to manage the return of obsolete material.

The need was to design a centralised, automated and dynamic system that ensured any material always redirected to the most recent technical data sheet.

The Solution

Within the Omnichannel Enablement team, a smart-link architecture was designed and implemented using Salesforce Marketing Cloud, combining CloudPages, AMPscript and dynamic-content automation.

1. Dynamic redirection architecture

  • A structure of master URLs was created to act as single access points for each product or technical data sheet.
  • Each URL is hosted on an SFMC CloudPage, configured to automatically redirect to the most recent version of the technical data sheet stored in the internal database.
  • The destination is updated in real time from a master table in SFMC, ensuring that even if the printed or digital link is old, it will always lead to the most up-to-date information.

2. Automating the maintenance of technical data sheets

  • A management panel was developed within SFMC that allows the medical team to upload and update links without technical intervention.
  • Thanks to AMPscript, redirects are updated immediately across all linked materials.
  • A review and validation workflow was established that automatically notifies the compliance teams whenever a data sheet is modified or a new version is published.

3. Scalability and international rollout

  • The system was designed to be modular and scalable, adaptable to different markets and products.
  • Printed materials, emails and digital banners shared the same dynamic URLs, ensuring consistency across all channels.
  • Local teams only needed to keep a single central reference up to date, eliminating the need to replace hundreds of materials each year.

4. Cross-departmental collaboration and regulatory alignment

  • The project was developed in close collaboration with the Medical, Marketing, Compliance and IT teams, ensuring each step was validated against regulatory requirements.
  • A validated update protocol was established that complies with internal medical-review standards and European regulatory requirements.

Results

  • A drastic reduction in operational costs by eliminating the need to reprint and destroy obsolete materials.
  • Estimated annual savings of 35–40% in the production and logistics of physical materials.
  • Total elimination of the compliance risk, guaranteeing that all references redirect to the current version of the technical data sheet.
  • Improved cross-departmental efficiency, reducing reaction times to regulatory updates.
  • A contribution to sustainability by reducing the volume of physical material withdrawn and destroyed.
  • Global adoption of the model as a best practice by other markets and medical departments.

The project represented a cultural shift: moving from a reactive and costly model to a proactive, automated and fully compliant system, where technology protected the company’s scientific and reputational integrity.